Pharmacoeconomics

Introduction & rationale

• Definition — branch of health economics that identifies, measures and compares the costs (resources consumed) and consequences (clinical, economic, humanistic outcomes) of pharmaceutical products and services to the health system and society — a value-for-money science comparing cost of treatment modalities to outcome.
• Comparative discipline — a cost or outcome is meaningless in isolation — it acquires meaning only against a defined comparator (current standard practice, placebo/no treatment, or best supportive care).
• Driving rationale — resource scarcity — finite resources, near-infinite demand, so rationing (explicit or concealed) is unavoidable; the policy question is not whether to ration but what form it should take. Pharmacoeconomics gives a planned, transparent, fair basis instead of an unregulated power struggle.
• Prescriber as economic agent — “money spent on prescribing is not available for another purpose” — every prescription is a resource-allocation decision.
• Fourth hurdle — beyond the three licensing criteria (quality, safety, efficacy) a product must additionally demonstrate cost-effectiveness before adoption/reimbursement; goals — best outcome per money spent, better allocation of finite funds, and incorporating quality of life into policy.